Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).

TSXV:SBM - Post by User

Sirona Biochem Corp > New info out

<< Previous

Bullboard Posts

Next >>

Comment by wexworthon Jan 07, 2021 11:24am

155 Views

Post# 32242108

RE:RE:RE:RE:RE:RE:RE:New info out

no, they said that production would begin later in 2020, the ramp up full production capacity in 2021 to meet demand for significant quantities - it's in a news release. The fact that Wuxi is now in production mode is the key trigger between interim supply (roowin) and core production supply (Wuxi). We need to settle down and let it all come to light.

<< Previous

Bullboard Posts

Next >>

New glaucoma treatment studied in a $3.4 billion market